Search - tctmd.com

Displaying 461 - 480 of 628

Sort: Relevancy | Date

News Daily News

Bioresorbable Scaffold Performs Well in Select STEMI Patients

January 22, 2014

News Daily News

Andamio Bioabsorbible Funciona Bien en Pacientes STEMI Seleccionados

January 22, 2014

Presentation TCT 2013

Mortality Trumps All: Ticagrelor for (Nearly) All!

Presenter: Michel Le May

October 31, 2013

Presentation TCT 2013

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Presenter: Dimitrios Alexopoulos

October 31, 2013

News Conference News TCT 2013

Studies Find Differing Benefits of Platelet, Genotype Testing

October 31, 2013

Presentation TCT 2013

Pre-load wtih Platelet ADP Receptor Inhibition in STEMI: Prasugrel, Ticagrelor, Clopidogrel, Or Does it Matter?

Presenter: Michel Le May

October 30, 2013

News Industry News

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

October 30, 2013

News Conference News TCT 2013

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

October 30, 2013

Presentation TCT 2013

No! Aspirin and Ticagrelor Is a Much Better Option

Presenter: Emmanouil Brilakis

October 28, 2013

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

News Daily News

Un Estudio Desafía las Directrices sobre Retrasos en Cirugías No Cardíacas tras PCI

L.A. McKeown

October 11, 2013

News Daily News

Study Challenges Guidelines Regarding Delay for Noncardiac Surgery After PCI

L.A. McKeown

October 11, 2013

News Daily News

ESC Consensus Statement Outlines Proper Role of Platelet Function Testing After PCI

September 30, 2013

News Daily News

El Cilostazol es Seguro como la Dosis Doble de Clopidogrel en Pacientes sometidos a PCI con un SLF

Yael L. Maxwell

September 20, 2013

News Daily News

Cilostazol as Safe as Double-Dose Clopidogrel in Patients Undergoing PCI with DES

Yael L. Maxwell

September 20, 2013

News Conference News ESC 2013

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

Yael L. Maxwell

September 03, 2013

News Conference News ESC 2013

TAO: Otamixaban Fails to Outshine Heparin Plus Eptifibatide in NSTE-ACS

Caitlin E. Cox

September 01, 2013

News Conference News ESC 2013

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

Yael L. Maxwell

September 01, 2013

News Daily News

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

August 30, 2013

News Daily News

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

August 30, 2013

Advertisement

Bioresorbable Scaffold Performs Well in Select STEMI Patients

Andamio Bioabsorbible Funciona Bien en Pacientes STEMI Seleccionados

Mortality Trumps All: Ticagrelor for (Nearly) All!

Emerging Ticagrelor Data: Insights Into its Safety and Efficacy Profile

Studies Find Differing Benefits of Platelet, Genotype Testing

Pre-load wtih Platelet ADP Receptor Inhibition in STEMI: Prasugrel, Ticagrelor, Clopidogrel, Or Does it Matter?

Study Find Pre-Hospital Administration of Bivalirudin Substantially Improves Outcomes Compared to Heparin in Heart Attack Patients

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

No! Aspirin and Ticagrelor Is a Much Better Option

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Un Estudio Desafía las Directrices sobre Retrasos en Cirugías No Cardíacas tras PCI

Study Challenges Guidelines Regarding Delay for Noncardiac Surgery After PCI

ESC Consensus Statement Outlines Proper Role of Platelet Function Testing After PCI

El Cilostazol es Seguro como la Dosis Doble de Clopidogrel en Pacientes sometidos a PCI con un SLF

Cilostazol as Safe as Double-Dose Clopidogrel in Patients Undergoing PCI with DES

CHAMPION: Cangrelor Bests Clopidogrel in PCI Patients in Large Meta-analysis

TAO: Otamixaban Fails to Outshine Heparin Plus Eptifibatide in NSTE-ACS

ACCOAST: Prasugrel Pretreatment Increases Bleeding in NSTE-ACS

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content